Lactobacillus Reuteri ATCC55730 In Cystic Fibrosis

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 60
Gender Both Genders
Age Range 13-17, 18-29
Notes for this study:
Supplementation of 10^10^ CFU _L. reuteri_ ATCC 55730 in persons with cystic fibrosis failed to alter pulmonary capacity or sputum (symptoms of cystic fibrosis) relative to placebo, although the amount of pulmonary exacerbations seen during supplemetnation was greatly reduced from 11 events in placebo (out of 30 persons) down to a lone event with supplementation.

Risk of upper respiratory tract infection was also significantly reduced in these persons, with no alterations in gastrointestinal tract infection risk.